Activation-Induced Killer Cell Immunoglobulin-like Receptor
3DL2 Binding to HLA–B27 Licenses Pathogenic T Cell
Differentiation in Spondyloarthritis

Anna Ridley,1 Hiroko Hatano,1 Isabel Wong-Baeza,2 Jacqueline Shaw,1
Katherine K. Matthews,3 Hussein Al-Mossawi,1 Kristin Ladell,4 David A. Price,5
Paul Bowness,1 and Simon Kollnberger6

Objective. In the spondyloarthritides (SpA), increased numbers of CD4+ T cells express killer cell immunoglobulin-like receptor 3DL2 (KIR-3DL2). The aim of this study was to determine the factors that induce KIR-3DL2 expression, and to characterize the relationship between HLA–B27 and the phenotype and function of KIR-3DL2–expressing CD4+ T cells in SpA.

Methods. In total, 34 B27+ patients with SpA, 28 age- and sex-matched healthy controls (20 B27− and 8 B27+), and 9 patients with rheumatoid arthritis were studied. KIR-3DL2 expression and other phenotypic characteristics of peripheral blood and synovial fluid CD4+ T cells were studied by flow cytometry, quantitative polymerase chain reaction, and Western blotting. T cell receptor clonality was determined by template-switch anchored reverse transcription–polymerase chain reaction and sequencing analysis. Cytokines were measured by enzyme-linked immunosorbent assay.

Results. Cellular activation induced KIR-3DL2 expression on both naive and effector CD4+ T cells. KIR-3DL2 binding to B27+ cells promoted expression of KIR-3DL2, the Th17-specific transcription factor retinoic acid receptor–related orphan nuclear receptor γt, and the antiapoptotic factor B cell lymphoma 2. KIR-3DL2+CD4+ T cells in patients with ankylosing spondylitis were oligoclonal and enriched for markers of T cell activation and for the gut homing receptor CCR9. In the presence of B27+ antigen-presenting cells, KIR-3DL2+CD4+ T cells produced less interleukin-2 (IL-2) but more IL-17. This effect was blocked by HC10, an antibody that inhibits the binding of KIR-3DL2 to B27 heavy chains.

Conclusion. KIR-3DL2 binding to HLA–B27 licenses Th17 cell differentiation in SpA. These findings raise the therapeutic potential of targeting HLA–B27–KIR-3DL2 interactions for the treatment of B27+ patients with SpA.

The spondyloarthritides (SpA) encompass a group of chronic inflammatory arthritic disorders typi-
fied by ankylosing spondylitis (AS), a condition in which up to 94% of affected individuals express the class I molecule HLA–B27 (1). Genome-wide association studies in AS have confirmed the key association with HLA–B27, and identified polymorphisms in genes associated with interleukin-17 (IL-17)–mediated immune responses, including IL-1 receptor (IL-1R) and IL-23R (2,3). Additional studies have shown raised levels of serum and synovial fluid IL-17 in patients with SpA (4,5), and raised numbers of circulating Th17 cells (6). However, the link between HLA–B27 and production of IL-17 by immune cells is poorly understood.

We have previously shown that HLA–B27 exists as β2-microglobulin (β2m)–free heavy chain forms, including heavy chain dimers (7,8). B27 free heavy chain molecules bind more strongly than other HLA class I proteins to the killer cell immunoglobulin-like receptor 3DL2 (KIR-3DL2), promoting increased survival of natural killer (NK) cells and CD4+ T cells (9–11). Increased proportions of NK cells and CD4+ T cells expressing KIR-3DL2 are present in individuals with SpA (10,12,13). These KIR-3DL2+CD4+ T cells are enriched for the expression of IL-17 and IL-23R, as well as for other Th17 cell markers, and produce interferon-γ (IFNγ). Moreover, the majority of all IL-23R+ IL-17–producing peripheral blood CD4+ T cells in patients with SpA reside in the minority KIR-3DL2+ T cell compartment (13).

In the present study, we show that CD4+ T cells up-regulate cell surface KIR-3DL2 expression upon activation. Subsequent binding of KIR-3DL2 to HLA–B27 maintains the expression of KIR-3DL2 and promotes T cell survival and Th17 cell differentiation. In addition, we provide evidence that this mechanism is proinflammatory in SpA.

PATIENTS AND METHODS

Patient and control samples. Samples of heparinized venous blood (25 ml) were obtained from 34 B27+ patients with SpA, 33 with definite AS fulfilling the modified New York criteria (14), 20 B27– and 8 B27+ healthy controls, and 9 disease controls with rheumatoid arthritis (RA). Patient and control demographics and medications are shown in Supplementary Table 1 (available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39515/abstract). Ethics permission was obtained from the Central Office for Research Ethics Committees (approval number 06/Q1606/139), and all subjects gave their individual written informed consent to participate.

Separation of CD4+ T cells. Peripheral blood and synovial fluid mononuclear cells were isolated by density-gradient centrifugation. Total or naive (CD45RO−) CD4+ T cells were separated by negative selection on magnetic beads (Miltenyi Biotec). CD4+ T cells were activated either with anti-CD2/CD3/CD28 beads (Miltenyi Biotec) or with 125 ng/ml phorbol myristate acetate (PMA) and 1 μg/ml ionomycin (Sigma).

CD4+ T cell coculture with antigen-presenting cells (APCs). LBL.721.221 and LBL.721.220 APC lines transfected with HLA–B*27:05 and other class I molecules were used, as has been described previously (8,15). Irradiated LBL.721 APCs (100,000 cells) were incubated with 200,000 naive or total CD4+ T cells (labeled with 5,6-carboxyfluorescein succinimidyl ester [Life Technologies]), followed by incubation with 100 ng/ml staphylococcal enterotoxin B (SEB; Sigma), as previously described (13). After 5–8 days, the cells were analyzed by flow cytometry, and supernatants were collected for enzyme-linked immunosorbent assays (ELISAs; eBioscience) to detect IL-2 and IL-17A. Irradiated APCs were removed after coculture, using a Dead Cell Removal kit (Miltenyi Biotec), and enriched T cells were processed for RNA extraction and quantitative polymerase chain reaction (qPCR).

For Th17 cell differentiation experiments, naïve T cells were cultured for 8 days at a 1:5 ratio with anti-CD2/CD3/CD28 beads or at a 1:2 ratio with transfected LBL.721.220 cells and 10 ng/ml SEB along with 20 IU/ml recombinant human IL-2 (rhIL-2; Peprotech) and 10 ng/ml rhIL-1, IL-6, and IL-23 (PeproTech) for 8 days. Supernatants were harvested for cytokine assay by ELISA, and T cells were analyzed by fluorescence-activated cell sorting (FACS) intracellular cytokine staining for the production of IL-2, IFNγ, and IL-17. Cells were treated with monensin (BD Biosciences) overnight before being stained for IL-2 and IFNγ, using protocols adapted from previously described methods (13). Cells were stimulated for 6 hours with monensin and PMA and ionomycin, and then stained for IL-17. For antibody-blocking experiments, cells were incubated with isotype control antibodies (IgG1/IgG2a; BioLegend) or HC10 (anti–class I heavy chain), HD6 (anti–B27 heavy chain), ME1 (anti–HLA–B27; binds β2m-associated B27), or DX31 (anti–KIR-3DL2) antibodies at 10 μg/ml. Antibodies were replenished after 3 days of cell culture.

T cell receptor (TCR) sequencing. Clonotypic analysis of isolated CD4+ T cell populations was performed as described previously, with minor modifications (16). Viable KIR-3DL2+ or KIR-3DL2− CD3+CD4+ T cells were sorted ex vivo into 1.5-ml microtubes (10,000 cells per tube; Sarstedt) containing 100 μl RNAlater (Applied Biosystems) using a FACSARia II flow cytometer (BD Biosciences). Unbiased amplification of all expressed TCRB gene products was conducted using a template-switch anchored reverse transcription–PCR with a 3’ constant region primer (5’-TGCTCAA ACAAGGAGACCT-3’). Amplicons were subcloned, sequenced, and analyzed as described previously (17). The ImMunoGeneTics nomenclature (18) was used for all sequenced gene products.

Flow cytometry. The following antibodies were used for flow cytometric analyses: IgG2a and anti-DX31 (AF647 in-house conjugates; provided by Jo Philips from DNAX Research Institute); PerCP-conjugated anti-CD3, fluorescent isothiocyanate (FITC)–conjugated anti-CD45RO, FITC-conjugated anti-CD69, FITC-conjugated anti-OX40, and phycoerythrin (PE)–conjugated anti-CCR6 (BD Biosciences); PE-conjugated anti–IL-17A and PE-CY7–conjugated anti-CD4 (eBioscience); and FITC-conjugated anti–IL-1R, FITC-conjugated anti–CCR9, and FITC-conjugated anti–IL-23R (R&D Systems). Dead cells were excluded using an allophycocyanin

GeneTics nomenclature (18) was used for all sequenced gene products, and analyzed as described previously (17). The ImMunoGeneTics nomenclature (18) was used for all sequenced gene products.
Figure 1. Expression of killer cell immunoglobulin-like receptor 3DL2 (KIR-3DL2) is induced upon CD4+ T cell activation, and KIR-3DL2 expression is correlated with T cell activation in patients with spondyloarthritis (SpA). A and B, Flow cytometry plots show staining of purified CD4+ T cells from a healthy control (HC) for the expression of KIR-3DL2 before and 6 hours after stimulation with phorbol myristate acetate (PMA) and ionomycin (Ion) (A) or the expression of KIR-3DL2 and OX40 before and 6, 24, or 48 hours after stimulation with anti-CD2/CD3/CD28 beads (B). Representative results from 1 of 3 independent experiments are shown. C, Flow cytometry plots show staining for the expression of OX40 on peripheral blood KIR-3DL2− or KIR-3DL2+ CD4+ T cells from a patient with ankylosing spondylitis (AS). IgG1 and IgG2a antibodies were used as isotype controls in the flow cytometry analyses. D, The percentage of OX40+CD4+ T cells expressing KIR-3DL2 was determined in the peripheral blood from patients with AS (n = 15), B27− healthy controls (n = 15), B27+ healthy controls (n = 8), and patients with rheumatoid arthritis (RA) (n = 9) (left) or in matched peripheral blood mononuclear cell (PBMC) and synovial fluid mononuclear cell (SFMC) samples from 5 patients with SpA (right). Values are the mean ± SD. P values were determined by analysis of variance.
The text describes a study on KIR-3DL2 expression in CD4+ T cells in patients with SpA (spondyloarthritis), comparing them to healthy controls and those with RA (rheumatoid arthritis). The study includes methods for gene expression analysis by qPCR and Western blotting, statistical analysis, and results showing increased KIR-3DL2 expression in CD4+ T cells from patients with SpA compared to healthy controls and RA patients.

**RESULTS**

Induction of KIR-3DL2 expression upon CD4+ T cell activation, and correlation between KIR-3DL2 expression and T cell activation in patients with SpA. The study detected an expansion of Th17 cells expressing KIR-3DL2 in patients with SpA (13). It was determined whether T cell activation was sufficient to induce KIR-3DL2 expression. After stimulation of human CD4+ T cells with PMA and ionomycin for 6 hours, KIR-3DL2 expression was markedly increased. KIR-3DL2 expression on CD4+ T cells was also increased after stimulation with anti-CD2/CD3/CD28 beads, reaching a maximum level of expression at 48 hours. Activated naive KIR-3DL2+ CD4+ T cells also expressed CD69 and OX40.

Statistical analysis showed that freshly isolated naive T cells expressed KIR-3DL2 and that the expression was upregulated after activation with PMA and ionomycin, reaching a maximum level of expression at 48 hours.

Oligoclonal TCR repertoire of KIR-3DL2+ CD4+ T cells in patients with SpA. The study compared the TCR sequences from patients with SpA, healthy controls, and RA disease controls, and found a significant increase in the proportion of CD4+ T cells expressing KIR-3DL2 in patients with SpA compared to healthy controls and RA patients.
KIR-3DL2–HLA–B27 BINDING LICENSES T CELL DIFFERENTIATION IN SpA

Figure 2. Expression of KIR-3DL2 is induced by activation of naive CD4+ T cells. A, Flow cytometry plots show staining for KIR-3DL2 or KIR-3DL1 and CD69 in purified naive CD4+ T cells from a patient with AS before and 6 hours after stimulation with PMA and ionomycin. B, Flow cytometry plots show staining for KIR-3DL2 and OX40 in naive CD4+ T cells from a healthy control before and 6, 24, or 48 hours after stimulation with anti-CD2/CD3/CD28 beads as compared to unstimulated control cells. IgG1 and IgG2a antibodies were used as isotype controls in the flow cytometry analyses. C, Western blots show the expression of KIR-3DL2, as compared to β-actin, before or after activation of purified naive CD4+ T cells from a healthy control with anti-CD2/CD3/CD28 beads for 6 hours, 24 hours, 2 days, 5 days, 8 days, or 12 days, with PMA and ionomycin for 6 hours, or with phytohemagglutinin (PHA) for 24 hours. Representative results from 1 of 3 independent experiments are shown. See Figure 1 for other definitions.

in CD4+ T cells from patients with SpA and healthy controls are listed in Supplementary Table 2 (http://onlinelibrary.wiley.com/doi/10.1002/art.39515/abstract). KIR-3DL2+CD4+ T cells from B27+ patients with SpA (n = 4) displayed an oligoclonal TCR repertoire, with evidence of skewing toward dominant clonotypes.
Synovial fluid KIR-3DL2+CD4+ T cells from patients with AS were oligoclonal (Figure 3A). In contrast, KIR-3DL2− CD4+ T cells purified from healthy controls exhibited more diverse TCR repertoires (Figure 3C). Overall, the mean ± SEM numbers of unique TCR sequences in the KIR-3DL2+ and KIR-3DL2− T cell compartments in patients with SpA (n = 5) were 19.8 ± 10.5 and 39.2 ± 9.43, respectively (P = 0.04, by paired t-test). In contrast, the mean ± SEM numbers of unique TCR sequences in the KIR-3DL2+ and KIR-3DL2− CD4+ T cell populations in the control group (n = 3) were not significantly different (36.67 ± 7.06 and 33 ± 11.02, respectively). Identical clonotypes were detected across the KIR-3DL2+ and KIR-3DL2− T cell compartments in 3 individuals (Figure 3D and Sup-
Promotion of KIR-3DL2 expression and Th17 cell differentiation by CD4+ T cell activation in the presence of HLA–B27. We next activated naive CD4+ T cells from patients with AS and healthy controls with SEB in the presence of LBL.721.221 or LBL.721.220 B cell

Figure 4. Binding of KIR-3DL2 to B27 heavy chains promotes the survival of activated naive CD4+ T cells. A, Left, Flow cytometry plots show staining for KIR-3DL2 or IgG2a isotype control in CD45RO+ T cells from a patient with AS after 5 days of stimulation with LBL.721.220 cells (transfected with HLA–B7 [220B7] or HLA–B27 [220B27]) and staphylococcal enterotoxin B (SEB). Right, KIR-3DL2 expression in cells under each condition is shown as the percentage of maximum (Max). B, OX40+KIR-3DL2+ naive CD4+ T cells from a healthy control were analyzed by Live/Dead staining to exclude dead cells (left) and identify viable cells (right), after 5 days of stimulation with the indicated LBL.721.220 cells and SEB. Nontransfected LBL.721.220 cells (220) were used as a transfection control. Isotype control monoclonal antibody (mAb) did not stain (results not shown). C, CD69+KIR-3DL2+ T cells among naive CD4+ T cells from a healthy control were analyzed by Live/Dead staining to exclude dead cells (top) and identify viable cells (bottom), after 2 days of stimulation with LBL.721.220 B27+ cells and SEB with or without the indicated mAb. In the flow cytometry analyses, representative results from 1 of 3 independent experiments are shown. D, Bcl-2 expression was assessed by quantitative polymerase chain reaction in healthy control naive CD4+ T cells cocultured with the indicated LBL.721.221 cells and SEB for 6 or 24 hours. Results are the mean ± SEM of 5 independent experiments. P values were determined by analysis of variance. NS = not significant (see Figure 1 for other definitions).

Supplementary Table 2, http://onlinelibrary.wiley.com/doi/10.1002/art.39515/abstract). Given their identical nucleic acid sequences, it is likely that these T cells are the progeny of individual sister clones that dynamically regulate KIR-3DL2 expression.
lines, each of which expresses similar surface densities of different HLA class I molecules. Both LBL.721.220 B27+ cells and LBL.721.221 B27+ cells express high levels of B27 dimers and free heavy chains (7,8). Moreover, the KIR-3DL2 receptor expressed by NK cells or reporter cells binds equally strongly to B27 dimers and free heavy chains expressed by transfected LBL.721.220 and LBL.721.221 cells (9).

Although initial induction of KIR-3DL2 on CD4+ T cells occurred independently of the expressed HLA class I allele (results not shown), higher levels of KIR-3DL2 expression were maintained over time in the presence of B27+ APCs (Figure 4A). Naïve T cells activated with LBL.721.220 B27+ cell transfectants also expressed higher levels of KIR-3DL2 messenger RNA (mRNA), as assayed by qPCR (see Supplementary Figure 3, http://onlinelibrary.wiley.com/doi/10.1002/art.39515/abstract). In all cases, activated naïve KIR-3DL2+ cells expressed the effector memory T cell marker CD45RO (results not shown). Similar results were obtained with naïve CD4+ T cells from healthy controls (see Supplementary Figure 4, http://onlinelibrary.wiley.com/doi/10.1002/art.39515/abstract) and unsorted (bulk) CD4+ T cells (results not shown). Furthermore, these cells survived better after activation in the presence of LBL.721.220 B27+ cells, compared to stimulation with parental or control HLA class I-transfected LBL.721.220 cells (Figure 4B).

The class I heavy chain antibody HC10 inhibited the expression of KIR-3DL2 and concomitantly decreased the numbers of viable naïve or bulk CD4+ T cells stimulated with LBL.721.220 B27+ cells (Figure 4C and results not shown). The KIR-3DL2–specific antibody DX31 also inhibited survival of activated naïve CD4+ T cells (Figure 4C and Supplementary Figure 4, http://onlinelibrary.wiley.com/doi/10.1002/art.39515/abstract). In contrast, the ME1 antibody, which recognizes β2m-associated HLA-B27, did not affect KIR-3DL2 expression and cell survival of naïve T cells activated with LBL.721.220 B27+ cells (Supplementary Figure 4, http://onlinelibrary.wiley.com/doi/10.1002/art.39515/abstract). In addition, activation of naïve CD4+ T cells with LBL.721.221 B27+ cells significantly up-regulated Bcl2 transcript expression at 24 hours (Figure 4D). Thus, activation with B27+ APCs promotes naïve CD4+ T cell survival and expression of KIR-3DL2.

Inhibition of CD4+ T cell IL-2 production by KIR-3DL2 interactions with HLA–B27 leading to Th17 cell differentiation. We next examined the functional effect of KIR-3DL2 binding to HLA–B27 on CD4+ T cell lineage differentiation. It has been established that IL-2 inhibits the production of IL-17, and we previously demonstrated that KIR-3DL2 binding to HLA–B27 on LBL.721.220 B27+ cells promotes IL-17 production (13). Moreover, KIR ligation by HLA class I inhibits IL-2 production (19). Thus, we reasoned that KIR-3DL2 binding to B27 dimers on transfected cells could promote an IL-17–secreting phenotype by reducing CD4+ T cell production of IL-2. Consistent with this notion, LBL.721.221 B27+ cells consistently stimulated greater production of IL-17 and lower production of IL-2 by activated T cells than did parental LBL.721.221 cells or control transfectants (Figure 5A).

The increased production of IL-17 observed following stimulation of CD4+ T cells with LBL.721.221 B27+ and LBL.721.220 B27+ cells was inhibited by HLA class I heavy chain (HC10) antibodies and anti–KIR-3DL2 (DX31) antibodies (see ref. 13 and Supplementary Figure 5, http://onlinelibrary.wiley.com/doi/10.1002/art.39515/abstract). HC10 antibodies inhibited IL-17 production and promoted IL-2 production by CD4+ T cells that had been stimulated with LBL.721.220 B27+ cells (Figure 5B). We consistently observed lower production of IL-2 by CD4+ T cells when the cells were stimulated with LBL.721.220 B27+ cells as compared to when they were stimulated with LBL.721.221 B27+ cells. Compared to LBL.721.221 B27+ cells, LBL.721.220 B27+ cells express higher levels of B27 free heavy chains, which are capable of binding to KIR-3DL2 (8).

To extend this observation, we studied the effect of superantigen activation on CD4+ T cell differentiation. Activation of naïve T cells in the presence of B27+ APCs consistently increased RORC gene expression (a key Th17-specific transcription factor) by naïve CD4+ T cells, as compared to that following stimulation with parental LBL.721.220 cells or control transfectants (Figure 5C). The effect on RORC expression was apparent from 5 days after activation (results not shown).

We further reasoned that increased expression of RORC could promote the differentiation of Th17 cells. Accordingly, we compared IL-17 production by naïve T cells stimulated with LBL.721.220 B27+ cells and LBL.721.220 control transfectants, or anti-CD2/CD3/CD28 beads in the presence of the Th17 cytokines IL-23, IL-1, and IL-6, together with low concentrations of IL-2. Activation with LBL.721.220 B27+ cells and Th17 cytokines promoted greater production of IL-17 by naïve T cells compared to that with the other stimuli (Figure 5D and Supplementary Figures 5 and 6, http://onlinelibrary.wiley.com/doi/10.1002/art.39515/abstract). Naïve T cells activated with LBL.721.220 B27+ cells produced less IL-2 compared to that after stimulation with control LBL.721.220 cells (Figure 5D). IL-17 production by naïve T cells activated with LBL.721.220 B27+ cells and Th17 cytokines was inhibited by HC10 and DX31 antibodies.
Supplementary Figures 5 and 6, http://onlinelibrary.wiley.com/doi/10.1002/art.39515/abstract). FACS staining showed that naive CD4+ T cells activated with LBL.721.220 B27+ cells also produced less IL-2 compared to that produced by control LBL.721.220-stimulated naive CD4+ T cells (Figure 5D).

We also studied the effect of physiologic levels of HLA–B27 expressed by Epstein-Barr virus–transformed...
Figure 6. KIR-3DL2+CD4+ T cells from B27+ patients with AS are enriched for the expression of interleukin-1 receptor (IL-1R) and CCR9. A, Flow cytometry plots show IL-1R expression by peripheral blood KIR-3DL2− and KIR-3DL2+ CD4+ T cells from a representative patient with AS. IgG1 was used for isotype control staining. B, Left, Percentages of IL-1R+CD4+ T cells expressing KIR-3DL2 were determined in the peripheral blood of patients with AS (n = 15), B27− healthy controls (n = 15), B27− healthy controls (n = 8), and patients with RA (n = 8). Right, Gene expression of IL1R was assessed by quantitative polymerase chain reaction in KIR-3DL2− and KIR-3DL2− CD4+ peripheral blood T cells from a B27− healthy control and a patient with AS. Gene expression was normalized to that of CD3. Representative results from 3 independent experiments are shown. C, Flow cytometry plots show CCR9 expression by peripheral blood KIR-3DL2− and KIR-3DL2+ CD4+ T cells from a representative patient with AS. IgG2a was used for isotype control staining. D, Percentages of CCR9+CD4+ T cells expressing KIR-3DL2 were determined in the peripheral blood of B27+ patients with AS (n = 15), B27− healthy controls (n = 15), B27− healthy controls (n = 8), and patients with RA (n = 8). Values in B and D are the mean ± SEM. P values were determined by analysis of variance. See Figure 1 for other definitions.
B cell lines on the differentiation of naive T cells activated with Th17 cytokines and superantigen. Differentiation of naive T cells with B27-expressing B cell lines promoted greater production of IL-17 than differentiation with cell lines that did not express B27 (Supplementary Figure 7, http://onlinelibrary.wiley.com/doi/10.1002/art.39515/abstract). Production of IL-17 by naive T cells stimulated with B27+ B cell lines was inhibited by both anti-class I heavy chain and anti-KIR-3DL2 mAb (Supplementary Figure 7, http://onlinelibrary.wiley.com/doi/10.1002/art.39515/abstract).

We have previously shown that the mAb HD6, which recognizes B27 heavy chain dimers, inhibits IL-17 production by CD4+ T cells from patients with SpA (20). Compared to the HC10 mAb, HD6 has a lower avidity for B27 free heavy chains and recognizes a distinct epitope (Marroquin O, et al: unpublished observations). Our previous results have shown that HD6 inhibits the survival of KIR-3DL2+ T cells (9). In this study, we found that HD6 inhibited the survival of KIR-3DL2+CD4+ T cells in the peripheral blood of patients with SpA (see Supplementary Figure 8, http://onlinelibrary.wiley.com/doi/10.1002/art.39515/abstract).

Collectively, these results show that the interaction between KIR-3DL2 and B27+ APCs can skew the differentiation of CD4+ T cells toward a Th17 cell phenotype.

**Enrichment for gut homing and Th17 cell differentiation markers of KIR-3DL2+CD4+ T cells from patients with SpA.** We previously found that KIR-3DL2+CD4+ T cells in patients with SpA are enriched for the expression of the Th17 cell markers IL-23R and CCR6 (13). To extend these findings, we studied additional differentiation and homing markers by flow cytometry and qPCR. Peripheral blood KIR-3DL2+CD4+ T cells from patients with SpA were enriched for both IL-23R and CCR6 expression, at both the protein and transcript levels, as compared to KIR-3DL2−CD4+ T cells both from patients with SpA and from B27− healthy controls (see Supplementary Figure 9, http://onlinelibrary.wiley.com/doi/10.1002/art.39515/abstract). Representative flow cytometry data from a patient with AS revealed an enrichment of IL-1R expression on peripheral blood KIR-3DL2+CD4+ T cells (Figure 6A). Significantly greater expression of KIR-3DL2 on IL-1R+CD4+ T cells was detected in B27+ patients with AS and B27+ healthy controls compared to B27− healthy controls and RA disease controls (Figure 6B). KIR-3DL2+CD4+ T cells from patients with SpA also expressed higher levels of IL-1R mRNA (Figure 6B). Notably, we did not observe significant differences in cell surface expression levels of the Th17 phenotypic markers on CD4+ T cells lacking KIR-3DL2 in any of the groups studied.

Increased expression of the gut chemokine receptor CCR9 was also detected on peripheral KIR-3DL2+CD4+ T cells from patients with AS and B27+ healthy controls (Figures 6C and D). Remarkably, 40% of all circulating CCR9+CD4+ T cells in patients with SpA expressed KIR-3DL2 (Figure 6D). Moreover, CCR9 expression on synovial fluid KIR-3DL2+CD4+ T cells was elevated in patients with SpA (results not shown). Similar to our observations with Th17 phenotypic markers, we did not observe significant differences in the level of CCR9 expression on CD4+ T cells lacking KIR-3DL2 expression in any of the groups studied. Thus, the increased proportions of KIR-3DL2+IL-1R+ and CCR9+ CD4+ T cells observed in patients with SpA occurred as a consequence of the increased percentages of KIR-3DL2+CD4+ T cells.

KIR-3DL2+CD4+ T cells also were found to produce more IL-6 (Supplementary Figure 9, http://onlinelibrary.wiley.com/doi/10.1002/art.39515/abstract), but not IL-5 or IL-10 (results not shown), in response to stimulation with anti-CD2/CD3/CD28 beads.

**DISCUSSION**

In this study, we showed that KIR-3DL2 is transiently up-regulated on the surface of CD4+ T cells upon activation. Subsequent binding of KIR-3DL2 to B27 free heavy chains on the surface of APCs maintains receptor expression and promotes Th17 cell differentiation and IL-17 production. These results suggest a mechanism whereby HLA–B27 predisposes individuals to the development of SpA. Moreover, the presence of oligoclonal KIR-3DL2+CD4+ T cell populations expressing markers of activation and Th17 cell lineage commitment in the blood and joints of patients with SpA provides strong evidence that this process occurs in vivo.

KIR expression on CD8+ T cells following TCR ligation has been reported previously (21). Similarly, the results of this study show, for the first time, that KIR-3DL2 is expressed by CD4+ T cells in response to activation. Freshly isolated naive CD4+ T cells expressed low levels of KIR-3DL2 both transcriptionally and in protein form. However, surface up-regulation of KIR-3DL2 was detected within 6 hours of activation, indicating that rapid translational activity is induced upon stimulation. It is notable in this regard that the presence of KIR transcripts has been detected previously in T cells lacking surface expression of the encoded receptor (22). The KIR-3DL2 promoter region is unique among the KIR family gene promoters, as it incorporates multiple potential binding sites for NF-κB, which could play a role in activation-induced expression (23).
The presence of B27+ APCs both maintained KIR-3DL2 expression by CD4+ T cells and skewed differentiation toward a Th17 or Th1/Th17 phenotype. We consider this a form of “licensing” in terms of lineage commitment. T cells with both a Th1 and a Th17 phenotype have been observed in patients with Crohn’s disease (24) and in those with juvenile idiopathic arthritis (25). How might the interaction between KIR-3DL2 and HLA-B27 drive CD4+ T cells to produce IL-17? We propose that KIR-3DL2 binding to noncanonical B27 free heavy chains enhances RORγt (and Bcl-2) expression, perhaps through a net decrease in CD3-transduced signaling strength. Indeed, weak TCR signals promote Th17 responses (26). Consistent with this possibility, we observed reduced production of IL-2 by CD4+ T cells stimulated with B27+ APCs, a phenomenon that correlated temporally with the induction of KIR-3DL2. It is also established that IL-2 inhibits the production of IL-17 by CD4+ T cells (27). Accordingly, inhibition of KIR-3DL2 binding to B27 free heavy chains increased T cell production of IL-2 and decreased production of IL-17 by CD4+ T cells. Several observations further support this proposed mechanism. First, the ZAP70 kinase mutation in SKG mice attenuates TCR signaling and predisposes to a disease resembling SpA, through increased production of IL-17 and decreased production of IL-2 (28). Second, reduced production of IL-2 by T cells has been observed in AS (29,30). Third, dendritic cells from HLA-B27-transgenic rats display impaired conjugate formation and promote Th17 responses (31,32). These findings are consistent with an immunoregulatory role for cell surface B27 free heavy chains, which are expressed by transgenic rat dendritic cells (33).

We also show that KIR-3DL2+CD4+ T cells are enriched for expression of OX40 and for IL-6 production. Both IL-6 and OX40–OX40L interactions positively regulate Th17 responses (34). Notably, IL-6 levels are correlated with the levels of inflammation markers in SpA (35).

The oligoclonal and highly skewed TCR repertoires observed in KIR-3DL2+CD4+ T cell populations from patients with SpA further support the hypothesis that KIR-3DL2 induction occurs during a process of antigen-driven T cell activation. Intriguingly, we also detected identical clonotypes within individuals that were shared between the KIR-3DL2+ and KIR-3DL2− CD4+ T cell compartments. The presence of these nucleotide-identical sequences strongly suggests that individual T cell clones can dynamically modulate KIR-3DL2 expression. Differential functionality has also been described for T cell clones bearing different NK cell receptors in the synovial fluid of patients with SpA, although KIR-3DL2 was not included in that analysis (36).

KIR-3DL2+CD4+ T cells from synovial fluid samples were further enriched for IL-1R and OX40 expression as compared to matched samples from the peripheral blood. This finding suggests that activation-induced KIR-3DL2 expression could promote the survival of CD4+ T cells expressing IL-1R and IL-23R at sites of inflammation. The expression of OX40 by synovial KIR-3DL2+CD4+ T cells further supports our hypothesis that antigen-induced activation is a disease-relevant process in SpA. Consistent with this interpretation, we observed oligoclonal expansions in the synovial KIR-3DL2+CD4+ T cell subset in some patients with SpA. Trafficking of KIR-3DL2+CD4+ T cells between sites of inflammation and the periphery is supported by our observation of shared clonotypes in matched peripheral blood and synovial fluid KIR-3DL2+CD4+ T cells isolated from 2 patients with SpA. Moreover, the fact that KIR-3DL2+CD4+ T cells were enriched for CCR9 expression suggests a possible intestinal origin. It is notable in this regard that up to 70% of patients with AS exhibit subclinical terminal ileitis (37).

Despite the fact that up to 94% of individuals with AS express B27 (1), the mechanistic link that underlies this HLA-associated disease remains unexplained. Our data support a 2-step model, whereby T cell activation induces KIR-3DL2 expression, and subsequent interaction with B27 free heavy chains promotes Th17 cell differentiation and survival. The same process may also occur on NK cells and CD8+ T cells, both of which can express KIR-3DL2. In this scenario, the observed HLA linkage could be explained by the fact that KIR-3DL2 binds more strongly to B27 dimers and free heavy chains compared to other HLA class I heavy chains (9,38). It is likely that by priming T cells to produce IL-17, this mechanism could act in concert with other mechanisms that have been proposed to enhance Th17 cytokine production in SpA, such as promotion of the unfolded protein response by B27 (39). Collectively, these findings suggest that targeting HLA–B27–KIR-3DL2 interactions could be therapeutically beneficial in patients with SpA.

ACKNOWLEDGMENT

We thank Brenda Hartman for expert assistance with the graphics.
AUTHOR CONTRIBUTIONS

All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version for publication. Dr. Kollnberger had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.


Acquisition of data. Ridley, Hatano, Wong-Baeza, Shaw, Matthews, Al-Mossawi, Ladell, Price, Bowness, Kollnberger.


REFERENCES


